Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lundbeck Looks To Replace Lexapro Earnings Through Ovation Purchase

This article was originally published in The Pink Sheet Daily

Executive Summary

Acquisition will enhance Lundbeck’s CNS pipeline and add a needed U.S. specialty sales force.

You may also be interested in...



Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry

As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.

Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry

As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.

NeuroTherapeutics Taps Corporate Investors in $43 Million Series B Financing

With backing from GSK and Pfizer as well as traditional venture firms, NeuroTherapeutics Pharma plans to move a preclinical CNS drug into multiple clinical trials.

Related Content

Topics

UsernamePublicRestriction

Register

PS069093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel